Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HLX-1502
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502
Details : HLX-1502 is being evaluated through a mid-stage clinical trial study for the treatment of patients suffering from neurofibromatosis Type 1.
Product Name : HLX-1502
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2025
Lead Product(s) : HLX-1502
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery Platform
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Healx Partners with Sanofi To Explore Rare Diseases with AI Drug Discovery
Details : Under the agreement, Sanofi will provide data related to a late stage discontinued asset to identify new disease indications using Healnet, Healx’s AI-driven drug discovery platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 13, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Healx Announces $47M Series C and FDA Clearance for Neurofibromatosis Type 1 Trial
Details : The net proceeds will be used to advance the company's lead program HLX-1502 through a mid-stage clinical trial studyies for the treatment of patients with neurofibromatosis Type 1.
Product Name : HLX-1502
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 08, 2024
Lead Product(s) : HLX-0201
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Healx Receives Ind and Orphan Drug Designation for Fragile X Clinical Trial
Details : HLX-0201 was then validated in preclinical models of fragile X, where it was found to modify several behaviours similar to those that are exhibited in patients with the condition.
Product Name : HLX-0201
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2021
Lead Product(s) : HLX-0201
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable